<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180153</url>
  </required_header>
  <id_info>
    <org_study_id>ChinaBJCH_SOX_BTC</org_study_id>
    <nct_id>NCT01180153</nct_id>
  </id_info>
  <brief_title>Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)</brief_title>
  <official_title>An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with&#xD;
      unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To list in cases with unresectable, metastatic or locally advanced biliary tract or ampullary&#xD;
      adenocarcinoma that have not been treated before,confirm the efficacy and safety of combined&#xD;
      S-1/L-OHP regimen for the biliary tract or ampullary carcinoma, providing evidence-based&#xD;
      proof for the future treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>to evaluate objective response rate (ORR) of SOX regimen to BTC (Ampullary Adenocarcinoma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>to evaluate survival data of overall survival (OS),Progression free Survival(PFS), safety outcome of SOX regimen to BTC (Ampullary Adenocarcinoma)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>SOX: advanced BTC or ampullary carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 oxaliplatin</intervention_name>
    <description>S-1 (20mg, 25mg); L-OHP (50 mg)</description>
    <arm_group_label>SOX: advanced BTC or ampullary carcinoma</arm_group_label>
    <other_name>S-1 (20mg, 25mg); L-OHP (50 mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent has been signed by the subject itself;&#xD;
&#xD;
          2. Aged over 18;&#xD;
&#xD;
          3. With a definite pathological or cytological diagnosis of adenocarcinoma;&#xD;
&#xD;
          4. No pre-treatment (including radiotherapy, chemotherapy, immunotherapy, etc.). For&#xD;
             recurrent cases, if the subjects have received adjuvant chemotherapy without S-1 or&#xD;
             L-OHP after surgery and the time to the end date of adjuvant chemotherapy is over 6&#xD;
             months, they can also be enrolled;&#xD;
&#xD;
          5. Enhanced helical CT or MRI scanning shows a target lesion over 1cm within 14 days&#xD;
             before enrollment&#xD;
&#xD;
          6. Within 7 days before enrollment, baseline blood routine and biochemical indicators&#xD;
             meet the following criteria:&#xD;
&#xD;
               -  Hemoglobin ≥ 90g/L,&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L,&#xD;
&#xD;
               -  Platelets ≥ 100×109/L，&#xD;
&#xD;
               -  Serum total bilirubin &lt; 1.5 times of the upper normal limit,&#xD;
&#xD;
               -  Serum creatinine &lt; upper limit of normal,&#xD;
&#xD;
               -  Serum albumin ≥ 30 g/L;&#xD;
&#xD;
          7. Can receive oral administration;&#xD;
&#xD;
          8. Karnofsky(KPS) score ≥ 70 points;&#xD;
&#xD;
          9. Expected survival time is more than 90 days;&#xD;
&#xD;
         10. Women of childbearing age must receive urine or blood pregnancy test within 7 days&#xD;
             before randomization and the results are negative;&#xD;
&#xD;
         11. Male and female patients of appropriate reproductive age are willing to use reliable&#xD;
             contraception methods for contraception in the process of study till 30 days after&#xD;
             drug withdrawal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a severe drug allergy history (including mildly allergic to L-OHP, 5-FU,&#xD;
             FT207, 5-HT3 receptor antagonist);&#xD;
&#xD;
          2. Patients who participated or are participating in other clinical trials within 4 weeks&#xD;
             before enrollment;&#xD;
&#xD;
          3. Patients who have received blood transfusion, blood products and hematopoietic factor&#xD;
             preparations such as G-CSF within 15 days before enrollment;&#xD;
&#xD;
          4. Patients who have undergone a surgery within 15 days before enrollment, and its&#xD;
             effects have not been eliminated;&#xD;
&#xD;
          5. Patients with diarrhea;&#xD;
&#xD;
          6. Patients with a complication of active infection (infection causes a fever above 38&#xD;
             ℃);&#xD;
&#xD;
          7. Patients accompanied by dysphagia, complete or incomplete gastrointestinal&#xD;
             obstruction, active gastrointestinal bleeding and perforation, etc. that cause&#xD;
             difficulty in taking S-1 orally;&#xD;
&#xD;
          8. Patients with severe liver disease (e.g. active hepatitis, cirrhosis, etc.), renal&#xD;
             insufficiency, severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe&#xD;
             emphysema, etc.), or uncontrollable diabetes, hypertension and other chronic systemic&#xD;
             diseases;&#xD;
&#xD;
          9. Patients who have received long-term systemic steroid therapy (Note: short-term users&#xD;
             with steroid withdrawal &gt; 2 weeks can be selected);&#xD;
&#xD;
         10. Patients with brain metastases or suspected of brain metastases;&#xD;
&#xD;
         11. Patients with peripheral nervous system disorder or a history of significant mental&#xD;
             disorder and central nervous system disorder;&#xD;
&#xD;
         12. Heart disease of significant clinical symptoms, e.g. congestive heart failure,&#xD;
             coronary heart disease with significant symptoms, arrhythmia and hypertension that are&#xD;
             difficult to be controlled by drugs, or with an episode of myocardial infarction&#xD;
             within 6 months, or cardiac insufficiency;&#xD;
&#xD;
         13. Patients with pleural effusion, ascites, or pericardial effusion that needs drainage;&#xD;
&#xD;
         14. Pregnant or breast-feeding women, or male and female patients of appropriate&#xD;
             reproductive age who refuse to take contraceptive measures;&#xD;
&#xD;
         15. Patients who have suffered from other malignancies within 5 years, except basal cell&#xD;
             carcinoma and carcinoma in situ of uterine cervix that have already been cured;&#xD;
&#xD;
         16. Patients without legal capability, or who can not continue the study due to medical or&#xD;
             ethical reasons;&#xD;
&#xD;
         17. Patients who are determined not suitable to participate in this clinical trial by the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Li, Doctor</last_name>
    <phone>010-88121122</phone>
    <phone_ext>321</phone_ext>
    <email>xiaotong10241@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chin Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Li, Doctor</last_name>
      <phone>010-88121122</phone>
      <phone_ext>321</phone_ext>
      <email>xiaotong10241@sin.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Shen</last_name>
      <phone>010-59714220</phone>
      <email>ian97@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lin Shen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>August 11, 2010</last_update_submitted>
  <last_update_submitted_qc>August 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lin Shen</name_title>
    <organization>Beijing Cancer Hospital</organization>
  </responsible_party>
  <keyword>40 S-1/L-OHP</keyword>
  <keyword>biliary tract</keyword>
  <keyword>ampullary carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

